Magali Periquet

1.1k total citations
21 papers, 742 citations indexed

About

Magali Periquet is a scholar working on Physiology, Rheumatology and Neurology. According to data from OpenAlex, Magali Periquet has authored 21 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 10 papers in Rheumatology and 5 papers in Neurology. Recurrent topics in Magali Periquet's work include Lysosomal Storage Disorders Research (13 papers), Glycogen Storage Diseases and Myoclonus (10 papers) and Child Nutrition and Feeding Issues (5 papers). Magali Periquet is often cited by papers focused on Lysosomal Storage Disorders Research (13 papers), Glycogen Storage Diseases and Myoclonus (10 papers) and Child Nutrition and Feeding Issues (5 papers). Magali Periquet collaborates with scholars based in United States, France and United Kingdom. Magali Periquet's co-authors include Michael P. Collins, J. T. Kissel, Zarife Sahenk, Jerry R. Mendell, Haikady N. Nagaraja, Vera Novak, S. M. Bengtson Nash, Miriam Freimer, Sevim Erdem‐Özdamar and Gary Gronseth and has published in prestigious journals such as Neurology, Human Mutation and Journal of Neurology.

In The Last Decade

Magali Periquet

21 papers receiving 724 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Magali Periquet United States	9	416	318	178	161	115	21	742
Toyokazu Saito Japan	12	485 1.2×	310 1.0×	56 0.3×	222 1.4×	110 1.0×	42	869
Nicholas J. Silvestri United States	18	680 1.6×	79 0.2×	52 0.3×	136 0.8×	180 1.6×	52	1.1k
Karl Frontzek Switzerland	16	283 0.7×	107 0.3×	74 0.4×	43 0.3×	307 2.7×	31	768
Hisashi Narai Japan	15	312 0.8×	59 0.2×	35 0.2×	82 0.5×	120 1.0×	47	580
M. Kadlubowski United Kingdom	13	343 0.8×	180 0.6×	41 0.2×	229 1.4×	147 1.3×	22	755
Ling Weng China	15	120 0.3×	76 0.2×	35 0.2×	76 0.5×	179 1.6×	33	606
Teruo Shirabe Japan	15	146 0.4×	67 0.2×	55 0.3×	138 0.9×	226 2.0×	65	715
Rocco Cicciarello Italy	14	134 0.3×	70 0.2×	119 0.7×	100 0.6×	104 0.9×	34	497
Jianying Xi China	19	574 1.4×	62 0.2×	23 0.1×	119 0.7×	323 2.8×	88	1.0k
Pamela E. Rios Coronado United States	8	109 0.3×	145 0.5×	63 0.4×	50 0.3×	148 1.3×	10	618

Countries citing papers authored by Magali Periquet

Since Specialization

Citations

This map shows the geographic impact of Magali Periquet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magali Periquet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magali Periquet more than expected).

Fields of papers citing papers by Magali Periquet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magali Periquet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magali Periquet. The network helps show where Magali Periquet may publish in the future.

Co-authorship network of co-authors of Magali Periquet

This figure shows the co-authorship network connecting the top 25 collaborators of Magali Periquet. A scholar is included among the top collaborators of Magali Periquet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magali Periquet. Magali Periquet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berger, Kenneth I., Cristina Ivanescu, Jérôme Msihid, et al.. (2025). Defining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease. Journal of Neuromuscular Diseases. 12(4). 523–534. 2 indexed citations

Mozaffar, Tahseen, Lionel Riou França, Jérôme Msihid, et al.. (2024). Efficacy of avalglucosidase alfa on forced vital capacity percent predicted in treatment-naïve patients with late-onset Pompe disease: A pooled analysis of clinical trials. Molecular Genetics and Metabolism Reports. 40. 101109–101109. 1 indexed citations

Díaz‐Manera, Jordi, Derralynn Hughes, Sevim Erdem‐Özdamar, et al.. (2024). Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials. Molecular Genetics and Metabolism. 143(4). 108608–108608. 1 indexed citations

Berger, Kenneth I., Yin‐Hsiu Chien, Alberto Dubrovsky, et al.. (2024). Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry. Journal of Neurology. 271(8). 5433–5446. 5 indexed citations

Kishnani, Priya S., David Kronn, Shugo Suwazono, et al.. (2023). Higher dose alglucosidase alfa is associated with improved overall survival in infantile-onset Pompe disease (IOPD): data from the Pompe Registry. Orphanet Journal of Rare Diseases. 18(1). 381–381. 6 indexed citations

Boentert, Matthias, Shahram Attarian, Jordi Díaz‐Manera, et al.. (2023). Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa. Journal of Neuromuscular Diseases. 11(2). 369–374. 2 indexed citations

Hurbin, Fabrice, et al.. (2023). Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000‐L Scale in Participants with Pompe Disease: A Phase 3/4 Open‐Label Study. Clinical Pharmacology in Drug Development. 12(12). 1185–1193. 4 indexed citations

Roberts, Mark, Irina Proskorovsky, Patricia Guyot, et al.. (2023). CO122 Late-Onset Pompe Disease (LOPD) Patients Treated with Avalglucosidase Alfa Show Favorable Results Compared to Cipaglucosidase Alfa Plus Miglustat: Indirect Treatment Comparison. Value in Health. 26(6). S37–S38. 1 indexed citations

Kishnani, Priya S., Kristina An Haack, N. Armstrong, et al.. (2023). P374 COMET: effects of avalglucosidase alfa and treatment switch from alglucosidase alfa on week 145 QMFT individual item responses. Neuromuscular Disorders. 33. S151–S152. 1 indexed citations

10.

Díaz‐Manera, Jordi, Mazen M. Dimachkie, Emmanuelle Salort‐Campana, et al.. (2023). Nonparametric analysis of forced vital capacity in the COMET trial demonstrates superiority of avalglucosidase alfa vs alglucosidase alfa. Molecular Genetics and Metabolism. 138(2). 107077–107077. 1 indexed citations

11.

Berger, Kenneth I., Cristina Ivanescu, Jérôme Msihid, et al.. (2023). CO168 Defining Clinically Meaningful Thresholds (CMT) for Forced Vital Capacity (FVC) and Six-Minute Walk Test (6MWT) in Patients with Late-Onset Pompe Disease (LOPD). Value in Health. 26(6). S46–S46. 3 indexed citations

12.

Mozaffar, Tahseen, Lionel Riou França, Jérôme Msihid, et al.. (2022). Analysis of pooled data from clinical trials in treatment-naïve patients with late-onset Pompe disease (LOPD) to inform on the efficacy of avalglucosidase alfa. Molecular Genetics and Metabolism. 135(2). S86–S86. 1 indexed citations

13.

Bevilacqua, Jorge A., Alberto Dubrovsky, Marcondes C. França, et al.. (2020). The Latin American experience with a next generation sequencing genetic panel for recessive limb-girdle muscular weakness and Pompe disease. Orphanet Journal of Rare Diseases. 15(1). 11–11. 21 indexed citations

14.

Reuser, Arnold, Ans T. van der Ploeg, Yin‐Hsiu Chien, et al.. (2019). GAA variants and phenotypes among 1,079 patients with Pompe disease: Data from the Pompe Registry. Human Mutation. 40(11). 2146–2164. 53 indexed citations

15.

Periquet, Magali, et al.. (2009). Isolated vasculitis of the peripheral nervous system.. PubMed. 26(3 Suppl 49). S118–30. 32 indexed citations

16.

Barkhaus, Paul E., Magali Periquet, & Sanjeev D. Nandedkar. (2006). Influence of the surface EMG electrode on the compound muscle action potential.. PubMed. 46(4). 235–9. 16 indexed citations

17.

Collins, Michael P. & Magali Periquet. (2004). Non-systemic vasculitic neuropathy. Current Opinion in Neurology. 17(5). 587–598. 43 indexed citations

18.

Collins, Michael P., Magali Periquet, Jerry R. Mendell, et al.. (2003). Nonsystemic vasculitic neuropathy. Neurology. 61(5). 623–630. 99 indexed citations

19.

Augé‐Gouillou, Corinne, et al.. (2001). The wild-type conformation of the Mos-1 Inverted Terminal Repeats is suboptimal for transposition in bacteria. Molecular Genetics and Genomics. 265(1). 51–57. 41 indexed citations

20.

Periquet, Magali, Vera Novak, Michael P. Collins, et al.. (1999). Painful sensory neuropathy. Neurology. 53(8). 1641–1641. 284 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact